OSE Immunotherapeutics SA
OSE Immunotherapeutics SA focuses on the development of immunotherapies for immune activation and regulation in the fields of immuno-oncology and autoimmune diseases. Its products include Tedopi that is in Phase III clinical stage for the treatment of no…
Biotechnology
FR, Nantes [HQ]
Cash Flow Statements
12 Records · Starting from 2012In Million EUR. Margins, Growth Rates In %
| Metric | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||
| Operating Cash Flow (OCF) | -1.00 | - - | -1.00 | -4.00 | - - | -7.00 | 1.00 | 8.00 | -19.00 | -9.00 | -18.00 | -19.00 | |
| Operating Cash (Net) | -1.00 | - - | -1.00 | -4.00 | - - | -7.00 | 1.00 | 8.00 | -19.00 | -9.00 | -18.00 | -19.00 | |
| Accounts Receivable | - - | - - | - - | - - | - - | -12.00 | 2.00 | 1.00 | - - | - - | - - | - - | |
| Accounts Payable | - - | - - | - - | - - | - - | -4.00 | -2.00 | - - | -3.00 | - - | -1.00 | - - | |
|
Working Capital
|
- - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Change | - - | - - | - - | -1.00 | - - | 3.00 | -4.00 | 8.00 | -2.00 | 1.00 | -3.00 | - - | |
| Other WC | - - | - - | - - | -1.00 | - - | 19.00 | -4.00 | 6.00 | - - | 2.00 | -1.00 | -2.00 | |
| Investing Activities | |||||||||||||
| Used Cash (Net) | - - | - - | - - | -5.00 | 6.00 | - - | - - | 2.00 | - - | - - | - - | - - | |
| Capital Expenditure | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Purchases of Investments | - - | - - | - - | -6.00 | - - | - - | - - | - - | - - | - - | - - | - - | |
| Sale/Maturity of Investment | - - | - - | - - | - - | 2.00 | - - | - - | 2.00 | - - | - - | - - | - - | |
| Property, Plant, Equipment (P&PE) | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Acquisitions (Net) | - - | - - | - - | - - | 3.00 | - - | - - | - - | - - | - - | - - | - - | |
| Other Investing Activities | - - | - - | - - | - - | 3.00 | - - | - - | - - | - - | - - | - - | - - | |
| Financing Activities | |||||||||||||
| Used Cash (Net) | - - | - - | -2.00 | -18.00 | -1.00 | -3.00 | - - | -4.00 | -23.00 | -14.00 | -10.00 | -13.00 | |
| Debt Repayment | - - | - - | - - | - - | - - | - - | - - | -5.00 | -6.00 | -15.00 | -11.00 | -2.00 | |
| Dividends Paid | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
|
Common Stock
|
- - | - - | - - | 18 | - - | - - | - - | - - | - - | - - | - - | - - | |
| Issued | - - | - - | 2.00 | 18.00 | - - | - - | - - | - - | 17.00 | - - | - - | 11.00 | |
| Repurchased | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Other Financing Activities | - - | - - | 2.00 | 1.00 | - - | 3.00 | - - | 10.00 | 12.00 | 29.00 | 21.00 | -5.00 | |
| Cash Balances | |||||||||||||
| Begin of Period | - - | - - | - - | 1.00 | 9.00 | 14.00 | 9.00 | 4.00 | 25.00 | 29.00 | 33.00 | 25.00 | |
| End of Period | - - | - - | 1.00 | 9.00 | 14.00 | 9.00 | 9.00 | 25.00 | 29.00 | 33.00 | 25.00 | 18.00 | |
| Change | - - | - - | - - | 8.00 | 5.00 | -5.00 | - - | 21.00 | 3.00 | 4.00 | -7.00 | -6.00 | |
| Non-Cash Balances | |||||||||||||
| Depreciation and Amortization | - - | - - | - - | - - | - - | - - | - - | - - | - - | 2.00 | 3.00 | 3.00 | |
| Stock Based Compensation | - - | - - | - - | 1.00 | - - | 1.00 | - - | 1.00 | 1.00 | 2.00 | 2.00 | 1.00 | |
| Other | - - | - - | - - | - - | -21.00 | - - | - - | - - | - - | - - | -3.00 | 6.00 | |
| Highlighted metrics | |||||||||||||
| Free Cash Flow (FCF) | -1.00 | - - | -1.00 | -4.00 | - - | -8.00 | - - | 8.00 | -19.00 | -10.00 | -18.00 | -19.00 | |
| Cash Conversion Cycle (CCC) | - - | - - | - - | 20,117.00 | -85,346.00 | - - | -598,110.00 | -195,381.00 | - - | - - | - - | - - | |
| Invested Capital | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
|
Other Operating Inflows/Outflows
|
|||||||||||||
| Forex Effect on Cash | - - | - - | - - | - - | - - | - - | - - | 5.00 | - - | - - | - - | - - |